908 related articles for article (PubMed ID: 17610809)
1. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
2. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Baxter L; Levitt G; Sullivan I; Clegg A
Eur J Cancer; 2007 Sep; 43(13):1959-66. PubMed ID: 17689066
[TBL] [Abstract][Full Text] [Related]
3. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Baxter L; Levitt G; Sullivan I; Clegg A
Br J Cancer; 2007 Jan; 96(2):226-30. PubMed ID: 17242696
[TBL] [Abstract][Full Text] [Related]
5. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Jan; (1):CD006647. PubMed ID: 19160293
[TBL] [Abstract][Full Text] [Related]
6. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
[TBL] [Abstract][Full Text] [Related]
8. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
[TBL] [Abstract][Full Text] [Related]
11. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
[TBL] [Abstract][Full Text] [Related]
15. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
16. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
17. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
[TBL] [Abstract][Full Text] [Related]
18. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
20. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]